Boston Biomedical Innovation Center

描述（由申请人提供）： 从学术界的生物医学发现到心血管、肺、血液和睡眠障碍的治疗、设备和诊断技术的临床应用和商业化，存在着一个公认的差距。造成这一鸿沟的原因是：用于支持早期开发所必需的概念验证或验证研究的资金不足;无法充分获得开发新技术所需的资源和专业知识;学术研究人员缺乏将新想法商业化的知识和经验。在本申请所包括的伙伴机构内，存在着建立基础设施所需的基本要素，以支持和维持发明从发现到开发和商业化的不间断、持久的流动。虽然这些机构在许多生物医学技术的开发方面有着非常成功的明确记录，但这些商业上的成功大多是靠个人发明者的顽强精神而不是靠坚定的机构机制的帮助取得的。我们建议通过建立区域性的波士顿中心来解决这些关键问题，该中心旨在加速心脏、肺、血液和睡眠疾病治疗、设备和诊断的创新（B-BIC，或波士顿生物医学创新中心）。该中心的主要目标是：1）开发一个综合基础设施，以扩大心脏、肺、血液和睡眠障碍的商业化技术领域; 2）通过参与将这些机会置于适当的评估环境中（“seed it”），征求（“find it”），选择（“挑选”）战略; 3）切实有效地将那些被选中的人从发展进程中带到适当的退出点;以及4）提供必要的教育和指导基础设施，以培养学术创新者的适当创业技能。通过实现这些目标，B-BlC将改变我们的学术环境的文化，以及公共和私营部门之间的关系，以促进心脏，肺，血液和睡眠障碍技术的成功发展战略，最终造福于患者和社会。 (End摘要）

DESCRIPTION (provided by applicant): A well-recognized gap exists in the path from biomedical discovery in academia to clinical application and commercialization of therapeutic, device, and diagnostic technologies in cardiovascular, pulmonary, hematologic, and sleep disorders. This chasm is the result of inadequate funding for support of proof-of concept or validation studies essential for early stage development; insufficient access to the resources and expertise needed to develop new technologies; and a lack of knowledge and experience among academic investigators in bringing new ideas to commercial realization. Within the partnering institutions included in this application, the essential elements exist with which to build the infrastructure needed to support and sustain the uninterrupted, durable flow of inventions from discovery through development and commercialization. While these institutions have a clear track record of remarkably successful development of many biomedical technologies, most of these commercial successes have been achieved by the tenacity of individual inventors rather than with the help of committed institutional mechanisms. We proposed to address these key shortcomings by establishing the regional Boston Center for Accelerated Innovation in Therapeutics, Devices, and Diagnostics for Heart, Lung, Blood, and Sleep Disorders (B-BIC, or the Boston Biomedical Innovation Center). The key objectives of this Center are to: 1) develop an integrated infrastructure that would expand the universe of commercializable technologies for heart, lung, blood, and sleep disorders; 2) place these opportunities in the proper evaluative context through an engagement ("seed it"), solicitation ("find it"), and selection ("pick it") strategy; 3) efficietly and effectively bring those selected to an appropriate exit point from the development process; and 4) provide the educational and mentoring infrastructure necessary for the development of the proper entrepreneurial skills among academic innovators. By achieving these goals, B-BlC would change the culture of our academic environment, as well as the relationship between the public and private sectors in facilitating successful development strategies for technologies in heart, lung, blood, and sleep disorders for the ultimate benefit of patients and society. (End of Abstract)